Kronos mulls ‘strategic alternatives’ after axing cancer drug development
The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...